News

Video

ENGOT-EN20/GOG-3083/XPORT-EC-042 – A Phase III, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced, or Recurrent Endometrial Carcinoma: Rationale, Methods, and Trial Design

Author(s):

Brian M. Slomovitz, MD

Brian Slomovitz, MD, MS, FACOG, presents the study design, rationale, and primary endpoints of ENGOT-EN20/GOG-3083/XPORT-EC-042, which will be evaluating the efficacy of selinexor compared with placebo as maintenance therapy in patients with advanced or recurrent TP53wt endometrial cancer.

Related Videos
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Phase 1 trial of DLL3/CD3 IgG-Like T-Cell Engager BI 764532 in Patients with DLL3 Positive Tumors: Patients with LCNEC
Phase 1/2 ARROS-1 study of zidesamtinib (NVL-520) in ROS1 fusion-positive solid tumors
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Real world evidence of treatment practices and therapeutic outcomes for newly diagnosed NSCLC patients with non-classical EGFR mutations demonstrates high unmet medical need
Phase 1 trial of DLL3/CD3 IgG-Like T-Cell Engager BI 764532 in Patients with DLL3 Positive Tumors: Patients with LCNEC
Phase 1 trial of DLL3/CD3 IgG-Like T-Cell Engager BI 764532 in Patients with DLL3 Positive Tumors: Patients with LCNEC
Matthew Powell, MD
Laura J. Chambers, DO
Brigatinib in NF2-Related Schwannomatosis with Progressive Tumors
Related Content
Matt Sause, chief executive officer, Roche Diagnostics
September 23rd 2024

CINtec PLUS Receives WHO Endorsement in Cervical Cancer Prevention Guidelines

Bradley J. Monk, MD, FACOG, FACS; Paolo Tarantino, MD
January 11th 2024

Monk and Tarantino Describe the Investigation of B7-H4 Vedotin–Directed ADCs in Gynecologic and Breast Cancers

State of the Science Summit - Gynecologic Cancers: Joshua G. Cohen, MD, FACOG, FACS
September 19th 2024

State of the Science Summit - Gynecologic Cancers: Joshua G. Cohen, MD, FACOG, FACS

R. Wendel Naumann, MD
October 26th 2023

Naumann Discusses Notable Research Efforts in Endometrial Cancer

Ana Oaknin, MD
September 18th 2024

Dato-DXd Demonstrates Efficacy, Safety in Platinum-Resistant Ovarian and Endometrial Cancers

FDA
September 16th 2024

FDA Lifts Partial Clinical Hold on Trials Evaluating Azenosertib in Advanced Solid Tumors